MINNEAPOLIS, Oct. 2, 2007 (PRIME NEWSWIRE) -- Vascular Solutions, Inc. (Nasdaq:VASC) today commented on the denial of cross-motions for summary judgment issued in the U.S. District Court in the Northern District of California in the patent litigation brought by VNUS Medical Technologies against Diomed, AngioDynamics and Vascular Solutions.
Howard Root, CEO of Vascular Solutions, commented: "The court in today's ruling denied VNUS's motion for summary judgment of infringement, leaving that issue for trial. The Court also denied all but one of the defendants' motions for summary judgment of invalidity. The Court deferred its ruling on defendants' remaining motion, which seeks a ruling that two of the three VNUS patents are invalid under the prior art as a matter of law. The Court asked VNUS to provide additional briefing, and indicated it would consider that remaining motion for summary judgment as of October 19. The trial is currently scheduled to commence on October 29 and last approximately three weeks before jury deliberation."
About Vascular Solutions
Vascular Solutions, Inc. is a medical device company that focuses on developing unique solutions for unmet clinical opportunities within vascular procedures. The company's five product categories consist of hemostat (blood clotting) products, extraction (clot removal) catheters, vein products, specialty catheters and access products. New products introduced since the second half of 2003 include the Vari-Lase endovenous laser product line for the treatment of varicose veins, the D-Stat Dry hemostatic bandage for the rapid control of topical bleeding, the Pronto extraction catheter for the aspiration of soft thrombus, the Langston dual lumen specialty catheter for the measurement of aortic stenosis and the Twin-Pass dual access specialty catheter for dual wire access in percutaneous procedures.
The information in this press release contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements. Important factors that may cause such differences include those discussed in our Annual Report on Form 10-K for the year ended December 31, 2006 and other recent filings with the Securities and Exchange Commission. The risks and uncertainties include, without limitation, risks associated with the need for adoption of our new products, limited working capital, lack of profitability, exposure to intellectual property claims, exposure to possible product liability claims, the development of new products by others, doing business in international markets, limited manufacturing experience, the availability of third party reimbursement, and actions by the FDA.
For further information, connect to www.vascularsolutions.com.